Slide 1: Third Quarter 2023 Operating & Financial Results Conference Call / Webinar
Third Quarter 2023 Operating & Financial Results Conference Call / Webinar November 8th, 2023 4:30 PM Eastern Time NASDAQ: LTRN
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements r
Slide 3: Contents and Speakers
Contents Speakers Panna Sharma David Margrave 01 Introduction CEO and President CFO 02 Q3 2023 Highlights 03 Financial Highlights 04 Q&A
Slide 4: Lantern is Transforming Drug Discovery Timelines & Costs with AI
Lantern is Transforming Drug Discovery Timelines & Costs with AI AI insights and Lantern can compress the biomarkers can increase timeline of early-stage drug the odds of clinical trial development by 70% and success by 12X* reduce the cost by 80% (*Parker et al., 2021) RADR® can predict and Lantern
Slide 5: Lantern's diverse & unique AI-driven pipeline of lead drug programs
Lantern’s diverse & unique AI-driven pipeline of 13 lead drug programs including the Phase 2 Harmonic™ trial and RADR® collaborations Lantern Pharma (NASDAQ: LTRN) Orphan Rare Pediatric Lead Program Indication Discovery Preclinical Phase I Phase II Designation Disease LP-300 Non-Small Cell Lung Canc
Slide 6: 3rd Quarter Highlights 1 of 2
2023 ü Received IND clearance from FDA to initiate Phase 1 clinical trial for LP-284, a first-in-human trial for 3rd Quarter advanced, refractory non-Hodgkin’s lymphomas (NHL). Highlights ü Dosed initial patient in Phase 1 with LP-184, a clinical trial for multiple advanced solid tumors that are ref
Slide 7: 3rd Quarter Highlights 2 of 2
2023 ü Developed initial proof-of-concept and preclinical evidence with our collaborators for a novel cryptophycin-based 3rd Quarter ADC (antibody-drug conjugate); initial data is planned to be shared in January 2024. Highlights ü Furthered development of Lantern’s AI platform, RADR®, 2of 2 to inclu
Slide 8: Financial Updates Q3 2023
Financial Updates Q3 2023 Solid financial position and capital efficiency fuel continued growth anticipated to provide a cash runway into at least Q3 of 2025 Summary Results of Operations Balance Sheet Highlights & Summary Three Months Ended September 30, (unaudited) 09/30/2023 12/31/2022 2023 2022
Slide 9: First-In-Human Trial for LP-284
LP-284: Ph. 1 trial launched in Q4 for recurrent NHLs with scarce therapeutic options & market potential of $4+ billion in annual global sales First-In-Human Trial for LP-284 Q2 Completed IND Recent Highlights 2023 enabling studies • Received notice of allowance from the USPTO for the composition of
Slide 10: Preclinical Data on Combination Therapy – LP-284
Preclinical Data on Combination Therapy – LP-284 LP-284 was highly synergistic when used in combination with rituximab in HGBL xenograft models High Grade B-cell Lymphoma (HGBL) Tumor Volumes in Mice LP-284 – in combination with rituximab HGBL have universally poor prognosis after chemotherapy, such
Slide 11: Phase 1A dose-escalation safety study of LP-184
Phase 1A dose-escalation safety study of LP-184 for patients with locally advanced or metastatic solid tumors or unresectable or recurrent glioblastoma multiforme (GBM) and other high-grade gliomas Annual US Market Potential: $14+ Billion 1 in 4 people have solid (DDR Deficient Solid Tumors) tumors
Slide 12: First-In-Human Trial for LP-184
LP-184: Launched Phase 1 basket trial for a blockbuster molecule with a market potential of $14+ billion in annual sales First-In-Human Trial for LP-184 LP-184 Phase 1A Trial Design June IND application 2023 cleared by FDA Dose Levels 1-4 (n ≥ 3, BOIN*) Clinicaltrials.gov (NCT05933265) Dose Level 5
Slide 13: Harmonic: Accelerating recruitment efforts for a growing indication
Harmonic™: Accelerating recruitment efforts for a growing indication with limited treatment options and an annual global market potential of $2.6+ bn Annual Market Potential (global) : $2.6+ Billion Trial Updates • Dr. Joseph Treat, MD of Fox Chase Cancer Center: appointed lead principal investigator
Slide 14: Expanding the Phase 2 Clinical Trial to East Asia
Expanding the Phase 2 Clinical Trial to East Asia: Boosting Patient Enrollment in Countries with High Incidences of NSCLC in Never Smokers Highlights of all lung cancer patients in East Asia • Expanding trial to South Korea, are never smokers* Taiwan, and Japan * Approximately • East Asian populatio
Slide 15: RADR collaboration with Bielefeld Univ. for cryptophycin ADCs
Initiated RADR® collaboration w/ Bielefeld Univ. to develop breakthrough cryptophycin ADCs - an entirely new treatment modality Rapidly growing global ADC market currently valued at Led by Professor $4+ billion Norbert Sewald, Ph.D. • RADR® ADC module will be leveraged to develop novel and potent pr
Slide 16: Recent Posters Highlighting Strong Validation of RADR Insights
Recent Posters Highlighting the Strong Validation of RADR® Insights, De-risking the Development of Lantern’s Drug Candidates Soho 2023 Annual Meeting Sep 2023 Targeting homologous recombination deficiencies in B-cell non-Hodgkin’s lymphomas with the novel anti-tumor small molecule LP-284 September,
Slide 17: RADR's expansion of size, scope, and capabilities
RADR®’s expansion of size, scope, and capabilities continues to push the boundary of AI for oncology drug discovery and development SCALE 50 billion oncology- focused datapoints by end of 2023 SCOPE • Additional classes of compounds including antibodies, checkpoint inhibitors, DNA damaging * agents,
Slide 18: Lantern Pharma's Proactive Engagement in Patient Outreach Initiatives
Lantern Pharma’s Proactive Engagement in Patient Outreach Initiatives Past Events Glioblastoma Awareness Day GO2 for Lung Cancer 5K Run in LA Social media campaign Sponsor July 2023 October 2023 World Lung Cancer Day BOHKY White Ribbon 5K Run White ribbon building @ Plano office Sponsor August 2023
Slide 19: 2023-24 Objectives
2023-24 Objectives A Transformational Year for Lantern ● Continue disciplined fiscal management T ● Explore licensing and partnership opportunities with biopharma companies O ● Establish additional RADR® based collaborations with corporate and research partners P ● Accelerate enrollment of The Harmo
Slide 20: IR Contact
IR Contact: IR@lanternpharma.com 1-972-277-1136 NASDAQ: LTRN www.lanternpharma.com @LanternPharma Sign up for Newsletter https://lantern-pharma.read.axioshq.com/signup/lantern-pharma-newsletter CONNECT WITH US